Uniwon PharmGen is a specialized R&D company focused on innovative molecular diagnostics using ribonucleic acid (RNA) and the development of innovative drugs based on mRNA. The company utilizes its proprietary targeted lipid nanoparticle nucleic acid delivery system to create an mRNA-lipid nanoparticle complex formation platform aimed at developing mRNA for cancer and degenerative disease treatments, positioning itself as a B2B-oriented venture.
The company holds foundational technologies for mRNA manufacturing and purification, essential for the removal of double-stranded RNA. By upgrading existing RNA therapeutic technologies with targeted ligands conjugated to lipid nanoparticles, they enhance the pharmacological efficacy of mRNA therapeutics while minimizing side effects. These advancements position Uniwon PharmGen to contribute uniquely to mRNA therapeutic development, offering the potential to effectively address various diseases.